Stock Events

Stock Events

Capricor Therapeutics 

$30.32
66
-$0.08-0.26% Today

Statistics

Day High
31.74
Day Low
30.18
52W High
40.37
52W Low
4.3
Volume
1,174,450
Avg. Volume
1,384,803
Mkt Cap
1.39B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.62
-0.47
-0.31
-0.16
Expected EPS
-0.515556
Actual EPS
N/A

Financials

-181.71%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
44.54MRevenue
-80.93MNet Income

Analyst Ratings

$49.67Average Price Target
The highest estimate is 63.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CAPR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, directly competing with Capricor's focus on cardioskeletal diseases and Duchenne muscular dystrophy.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including therapies for genetic diseases, competing in the same space as Capricor.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics focuses on the development of orally administered small molecule drugs that regulate gene expression, including treatments for muscular dystrophy, overlapping with Capricor's therapeutic areas.
Solid Biosciences
SLDB
Mkt Cap419.71M
Solid Biosciences is dedicated to solving Duchenne muscular dystrophy (DMD) and other neuromuscular diseases, directly competing with Capricor's DMD programs.
Forte Biosciences
FBRX
Mkt Cap160.88M
Forte Biosciences specializes in developing therapies for dermatological diseases but also explores treatments in other areas that could potentially overlap with Capricor's research in regenerative medicine.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, a large pharmaceutical company, has a broad range of products including in areas that compete with Capricor's niche, such as cardiovascular and rare diseases treatments.
Moderna
MRNA
Mkt Cap10.61B
Moderna, known for its mRNA technology, is exploring treatments in areas that could compete with Capricor, especially in regenerative medicine and rare diseases.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a diverse portfolio that includes vaccines and treatments for a variety of diseases, some of which may compete with Capricor's therapeutic areas.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk focuses on diabetes care but also has interests in hemophilia and growth disorders, potentially competing with Capricor's cardioskeletal and rare disease treatments.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, areas that overlap with Capricor's research interests in genetic and rare diseases.

About

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Frank Isaac Litvack FACC, M.D.
Employees
160
Country
US
ISIN
US14070B3096

Listings

F
DE
4LN2.F
XNAS
US
CAPR
BOATS
BOATS
CAPR.BOATS

0 Comments

Share your thoughts

FAQ

What is Capricor Therapeutics stock price today?▼
The current price of CAPR is $30.32 USD — it has decreased by -0.26% in the past 24 hours. Watch Capricor Therapeutics stock price performance more closely on the chart.
What is Capricor Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Capricor Therapeutics stocks are traded under the ticker CAPR.
Is Capricor Therapeutics stock price growing?▼
CAPR stock has risen by +1.71% compared to the previous week, the month change is a +8.88% rise, over the last year Capricor Therapeutics has showed a +220.95% increase.
What is Capricor Therapeutics market cap?▼
Today Capricor Therapeutics has the market capitalization of 1.39B
When is the next Capricor Therapeutics earnings date?▼
Capricor Therapeutics is going to release the next earnings report on May 07, 2026.
What were Capricor Therapeutics earnings last quarter?▼
CAPR earnings for the last quarter are -0.62 USD per share, whereas the estimation was -0.51 USD resulting in a -21.81% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Capricor Therapeutics revenue for the last year?▼
Capricor Therapeutics revenue for the last year amounts to 44.54M USD.
What is Capricor Therapeutics net income for the last year?▼
CAPR net income for the last year is -80.93M USD.
How many employees does Capricor Therapeutics have?▼
As of April 01, 2026, the company has 160 employees.
In which sector is Capricor Therapeutics located?▼
Capricor Therapeutics operates in the Health Care sector.
When did Capricor Therapeutics complete a stock split?▼
The last stock split for Capricor Therapeutics was on June 05, 2019 with a ratio of 1:10.
Where is Capricor Therapeutics headquartered?▼
Capricor Therapeutics is headquartered in San Diego, US.